Загрузка...
Future of targeted agents in metastatic colorectal cancer
Great strides have been made in improving the outcome of patients with metastatic colorectal cancer and targeted agents are an important part of the treatment arsenal. The approved monoclonal antibodies, bevacizumab, cetuximab and panitumumab, are part of the standard of care, yet only recently have...
Сохранить в:
| Главные авторы: | , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2012
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3834580/ https://ncbi.nlm.nih.gov/pubmed/24273599 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/crc.12.52 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|